CervoMed (CRVO) Projected to Post Earnings on Friday

CervoMed (NASDAQ:CRVO - Get Free Report) will likely be posting its quarterly earnings results before the market opens on Friday, April 4th. Analysts expect CervoMed to post earnings of ($0.67) per share and revenue of $1.79 million for the quarter.

CervoMed (NASDAQ:CRVO - Get Free Report) last released its quarterly earnings results on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.13). CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%. The business had revenue of $2.16 million for the quarter, compared to the consensus estimate of $1.51 million. On average, analysts expect CervoMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CervoMed Price Performance

Shares of CervoMed stock traded up $0.98 during trading on Friday, hitting $9.48. The company's stock had a trading volume of 1,051,230 shares, compared to its average volume of 1,260,367. The stock has a market cap of $82.50 million, a price-to-earnings ratio of -4.67 and a beta of 1.84. CervoMed has a 52 week low of $1.80 and a 52 week high of $25.92. The stock has a 50-day moving average price of $4.00 and a two-hundred day moving average price of $7.59.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Roth Capital raised CervoMed to a "strong-buy" rating in a research note on Thursday, December 5th. Brookline Capital Management raised shares of CervoMed from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, March 11th. Canaccord Genuity Group boosted their price target on shares of CervoMed from $12.00 to $21.00 and gave the stock a "buy" rating in a research report on Tuesday, March 18th. Chardan Capital raised shares of CervoMed from a "neutral" rating to a "buy" rating and set a $14.00 price objective on the stock in a research note on Thursday, March 13th. Finally, D. Boral Capital reissued a "buy" rating and set a $10.00 target price on shares of CervoMed in a research note on Wednesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $27.50.

Remove Ads

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.